NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

DCVax-L is likely to be quite cost effective as the cost covers years of coverage and the lack of side effects does not mushroom other costs. The UK giving DCVax-L the first designation of Promising Innovative Drug, first before drugs coming from the UK.

The doubt they would do that if they did not have strong reason to believe that this will be an innovative drug they hope to have approved by their national insurance program.

You can try to engineer worries, but let’s just focus on the facts. Unlike Car-T, where costs spiral out of control, DCVax-L offers a likely cost effective and symptom light to symptom-less way to treat patients cost effectively over years. Doctors, patients and I believe even insurers are going to like this treatment, which can be given at the doctors office in a quick in and out visit.